Clinical

Potential issues associated with insurance coverage and ways to navigate these challenges are discussed by medical experts.

The FDA announced it is allowing Florida to import medications in bulk from Canada at far lower prices than those offered in the United States; health insurance companies are revamping their technology to encourage more people to get their medications through the mail; nearly 17,000 patients with COVID-19 may have died after taking hydroxychloroquine during the first pandemic wave.

A topical therapy, PF-07038124 0.01%, administered once daily was more effective than the vehicle control in patients with atopic dermatitis (AD) and plaque psoriasis, a study finds.

Jonathan Silverberg, MD, PhD, MPH, of George Washington University School of Medicine and Health Sciences, explains the benefits of using Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).

The average direct cost for hospital treatment for patients with COVID-19 in the United States rose by 26% from 2020 to 2022; scientists have developed a new type of antibiotic to treat a deadly bacteria resistant to most current antibiotics; a survey conducted for Utah state officials gave some clues as to why millions of Americans lost Medicaid coverage last year.

Experts examine the economic burdens on the health care system, payers, and patients, based on associated costs with dry eye disease.

Panelists underscore the importance of patient education in improving treatment adherence.

Experts explore the efficacy and safety profiles of elacestrant, an oral selective estrogen receptor degrader (SERD), and other options for endocrine therapy. The panelists also discuss clinical trial insights, progression-free survival rates, and tolerability, highlighting outcomes and advances in metastatic breast cancer treatment.

Asthma and allergy drugs such as montelukast and cetirizine were among a list of drugs frequently implicated in major drug-drug interactions.

Key opinion leaders emphasize the role of coordinated care between dermatologists and oncologists in monitoring and managing adverse events related to immunotherapy in CSCC and BCC.

Dr Pisano shares insights on expanding dermatologists' comfort with immunotherapy through collaborative learning and collective expertise.

Ian Neeland, MD, of University Hospitals Harrington Heart & Vascular Institute, describes challenges patients with diabetes face during the semaglutide shortage and alternative options he gives his patients to prevent therapy disruptions.

Drugmakers are expected to increase prices on more than 500 drugs early this month; the FDA approved nearly 50% more novel drugs in 2023 than in 2022; the number of Americans who were not pregnant and wanted abortion pills increased by nearly 10 times after the Supreme Court’s 2022 Roe v Wade decision leaked.

A multidisciplinary team has proposed respiratory care guidance for pediatric and adult patients living with Duchenne muscular dystrophy (DMD) in the United Kingdom (UK), with these recommendations meant to optimize DMD care day to day and in acute episodes.

Elaine Siegfried, MD, of Saint Louis University School of Medicine, discusses how the recent guideline update by the American Academy of Dermatology (AAD) affects dermatologists' atopic dermatitis (AD) treatment decisions.

The study authors note that the Best Asthma Control Test for School Children and Adolescents (Best ACT-S) complements a previously developed questionnaire that assesses preschool-aged patients with asthma.

Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.

Our top coverage from the CHEST Annual Meeting 2023 explored various topics, including strategies to prevent air pollutant exposure and keys to achieving equity in lung cancer screenings.

This year’s most-read articles on atopic dermatitis (AD) explored different treatment and education methods.

In recently published data from the phase 3 PROTECT trial, teplizumab slowed the progression of type 1 diabetes in children and adolescents.

This year’s most-read articles on chronic obstructive pulmonary disease (COPD) explored a variety of topics concerning patients with COPD, including long-acting inhaler adherence and their risk of falling.

Just 8.5% of eligible patients were screened for hepatitis C virus (HCV); among them, 5.9% tested positive for the HCV antibody, and 3.0% had an active infection.

The most-read articles from the 2023 European Hematology Association (EHA) Annual Meeting covered the most up-to-date treatment strategies for hematological malignancies, racial disparities in treatment patterns for blood cancers, and updates on immunotherapy as a tool in hematologic oncology.

The researchers noted the need for strategies to better support women living with HIV with breast cancer during toxic therapies to improve outcomes among this growing population.

Mendelian randomization analyses demonstrated a causal relationship between hypothyroidism and diabetes, along with its related microvascular complications.